Neuropharmacology & Neurotherapeutics
Dimethyl fumarate was approved as a first-line oral treatment for relapsing forms of multiple sclerosis by the U.S. Food and Drug Administration in 2013. The most common adverse reactions for dimethyl fumarate as reported during clinical trials are flushing, mostly mild to moderate in nature, and gastrointestinal events. These events are most common at the start of therapy and usually decrease over time.
Nov. 02, 2020